Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.54 |
| ▸ | CTSK | P43235 | 1/20 | 0.54 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.53 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.48 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | GNPAT | O15228 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | PAM | P19021 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6191742 | 1.00 | CTSS (0.54) | CTSSCTSKGPR34FOLH1NLRP3 | |
| SCHEMBL2821322 | 1.00 | CTSS (0.54) | CTSSCTSKGPR34FOLH1NLRP3 | |
| SCHEMBL14462270 | 0.86 | FOLH1 (0.55) | GPR34FOLH1NLRP3PIN1MME | |
| SCHEMBL27307972 | 0.86 | FOLH1 (0.55) | GPR34FOLH1NLRP3PIN1MME | |
| SCHEMBL30834629 | 0.86 | FOLH1 (0.55) | GPR34FOLH1NLRP3PIN1MME | |
| SCHEMBL34461699 | 0.86 | FOLH1 (0.55) | GPR34FOLH1NLRP3PIN1MME | |
| SCHEMBL12247346 | 0.85 | FOLH1 (0.52) | GPR34FOLH1NLRP3L3MBTL1MME | |
| SCHEMBL27561728 | 0.85 | NLRP3 (0.53) | CTSSCTSKFOLH1NLRP3TACR1 | |
| SCHEMBL27484072 | 0.85 | NLRP3 (0.53) | CTSSCTSKFOLH1NLRP3TACR1 | |
| SCHEMBL23279751 | 0.84 | ACE (0.58) | CTSSCTSKGPR34PIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951943-B2 | Method for preparing and purifying 3-hydroxyamidinophenylalanine compounds | WILEX AG (DE) | 2011-05-31 | — | — | US | disclosed |
| EP-1799665-B1 | METHOD FOR CLEANING 3-HYDROXYAMIDINOPHENYLALANINE DERIVATIVES BY THE PRECIPITATION AND RECRYSTALLISATION OF A SALT AND AN AROMATIC SULPHONIC ACID | WILEX AG (DE) | 2009-08-19 | — | — | EP | disclosed |
| EP-1299365-B1 | 2-AMINOTHIAZOLINE DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2005-09-28 | — | — | EP | disclosed |
| US-6699895-B2 | CYCLIZING THE TERT-BUTYL-THIOUREA DERIVATIVE TO FORM THE END PRODUCT | AVENTIS PHARMA S.A. (FR) | 2004-03-02 | — | — | US | disclosed |
| EP-1299365-A1 | 2-AMINOTHIAZOLINE DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | Aventis Pharma S.A. (FR) | 2003-04-09 | — | — | EP | disclosed |
| US-20020198243-A1 | 2-aminothiazoline derivatives and process for preparing the same | CARRY JEAN-CHRISTOPHE (FR) | 2002-12-26 | — | — | US | disclosed |
| US-20020187987-A1 | Use of 2-aminothiazoline derivatives as inhibitors of inducible NO-synthase | CARRY JEAN-CHRISTOPHE (FR) | 2002-12-12 | — | — | US | disclosed |
| US-6451821-B1 | ADMINISTERING TO A PATIENT A THERAPEUTICALLY EFFECTIVE AMOUNT OF 2-AMINOTHIAZOLINE DERIVATIVES FOR TREATING OR PREVENTING DISEASE CONDITIONS ASSOCIATED WITH AN ABNORMAL PRODUCTION OF NITRIC OXIDE(NO) | AVENTIS PHARMA S.A. (FR) | 2002-09-17 | — | — | US | disclosed |
| US-20020022631-A1 | Use of 2-aminothiazoline derivatives as inhibitors of inducible no-synthase | AVENTIS PHARMA S.A. (FR) | 2002-02-21 | — | — | US | disclosed |
| WO-2001094325-A1 | 2-AMINOTHIAZOLINE DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022631-A1 | Use of 2-aminothiazoline derivatives as inhibitors of inducible no-synthase | NOS2, NOS3, NOS1 | CTSS 3866/4885CTSK 4438/4885GPR34 1380/4885 |
| US-20020198243-A1 | 2-aminothiazoline derivatives and process for preparing the same | NOS3, TH, CBR1 | CTSS 3131/4885CTSK 4019/4885GPR34 1448/4885 |
| US-20020187987-A1 | Use of 2-aminothiazoline derivatives as inhibitors of inducible NO-synthase | NOS2, NOS3, NOS1 | CTSS 3867/4885CTSK 4466/4885GPR34 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.